FDA's stance on compounding from bulk drugs challenged

被引:0
|
作者
不详
机构
关键词
D O I
暂无
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
引用
收藏
页码:1656 / 1657
页数:2
相关论文
共 50 条
  • [42] Efficiency indicators for new drugs approved by the FDA from 2003 to 2013
    Rossella Belleli
    Roland Fisch
    Thomas D. Szucs
    Nature Reviews Drug Discovery, 2015, 14 : 156 - 156
  • [43] FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022
    Rizzo, Carla
    Amata, Sara
    Pibiri, Ivana
    Pace, Andrea
    Buscemi, Silvestre
    Piccionello, Antonio Palumbo
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (09)
  • [44] Toward Better-Quality Compounded Drugs - An Update from the FDA
    Woodcock, Janet
    Dohm, Julie
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (26): : 2509 - 2512
  • [46] More Alzheimer’s drugs head for FDA review: what scientists are watching
    Asher Mullard
    Nature, 2021, 599 : 544 - 545
  • [47] Flexibility and innovation in the FDA's novel regulatory approval strategies for hematologic drugs
    Farrell, Ann T.
    Goldberg, Kirsten B.
    Pazdur, Richard
    BLOOD, 2017, 130 (11) : 1285 - 1289
  • [48] More Alzheimer's drugs head for FDA review: what scientists are watching
    Mullard, Asher
    NATURE, 2021, 599 (7886) : 544 - 545
  • [49] Navigating FDA's approach to approval of nanoparticle-based drugs and devices
    Duvall, Mark N.
    Wyatt, Alexandra M.
    Yeung, Felix S.
    Nanotechnology Law and Business, 2011, 8 (04): : 226 - 244
  • [50] Guidelines for pharmacotherapy in Alzheimer's disease - A primer on FDA-approved drugs
    Varadharajan, Ashvin
    Davis, Aarjith Damian
    Ghosh, Aishwarya
    Jagtap, Tejaswini
    Xavier, Anjo
    Menon, Anjana Jayakumar
    Roy, Dwaiti
    Gandhi, Sandhya
    Gregor, Thomas
    JOURNAL OF NEUROSCIENCES IN RURAL PRACTICE, 2023, 14 (04) : 566 - 573